Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Glitazones and atherosclerosis].

B Staels1

  • 1Département d'Athérosclérose, INSERM U545, Institut Pasteur de Lille, Faculté de Pharmacie, Université de Lille 2, F-59019 Lille Cedex, France. bart.staels@pasteur-lille.fr

Annales D'Endocrinologie
|June 17, 2005
PubMed
Summary

Glitazones, PPARgamma agonists, show promise in preventing atherosclerosis progression and cardiovascular events. These drugs may offer cardioprotection for diabetic and high-risk individuals by targeting inflammatory lesions and plaque rupture.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased 1-deoxysphingolipids caused by an altered plasma alanine to serine ratio are associated with metabolic dysfunction-associated steatotic liver disease (MASLD).

Metabolomics : Official journal of the Metabolomic Society·2025
Same author

Role of bile acid receptor FXR in development and function of brown adipose tissue.

Biochimica et biophysica acta. Molecular and cell biology of lipids·2022
Same author

[State of the art on the pathophysiology, diagnosis and treatment of non-alcoholic steatohepatitis (NASH)].

Annales pharmaceutiques francaises·2022
Same author

Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.

Acta diabetologica·2020
Same author

Best Poster Award - Second Prize: Bile Acids as Novel Vascular Signalling Molecules and Therapeutic Target.

European cardiology·2020
Same author

Peroxisome Proliferator-Activated Receptor <i>γ</i> Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages.

PPAR research·2017

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Context:

  • Atherosclerosis is a progressive vascular disease originating from inflammatory lesions and endothelial dysfunction.
  • It culminates in plaque rupture and thrombogenesis, posing significant cardiovascular risk.

Purpose:

  • To review the stages of atherosclerosis and their mechanisms.
  • To summarize studies on glitazones, PPARgamma agonists, in atherosclerosis.
  • To evaluate their potential cardioprotective effects in diabetic and high-risk patients.

Summary:

  • Glitazones target multiple stages of atherogenesis, including initial inflammation and later plaque events.
  • In vitro and in vivo studies, along with clinical trials in type 2 diabetes patients, support glitazones' cardioprotective role.
  • These agents may benefit both diabetic and non-diabetic individuals with metabolic syndrome or glucose intolerance.

Impact:

  • Glitazones represent a potential therapeutic strategy for managing atherosclerosis and reducing cardiovascular events.
  • This review highlights the multifaceted action of PPARgamma agonists in preventing atherogenesis.
  • Findings support the use of glitazones in at-risk populations beyond diabetes management.

Related Experiment Videos